Astrazeneca PLC (AZN) Stake Boosted by TD Asset Management Inc.
TD Asset Management Inc. increased its position in Astrazeneca PLC (NYSE:AZN) by 23.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 751,510 shares of the company’s stock after buying an additional 145,093 shares during the period. TD Asset Management Inc.’s holdings in Astrazeneca PLC were worth $24,694,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. Dodge & Cox raised its stake in Astrazeneca PLC by 24.9% in the second quarter. Dodge & Cox now owns 32,532,723 shares of the company’s stock valued at $982,163,000 after buying an additional 6,483,073 shares in the last quarter. Capital International Investors boosted its stake in shares of Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock worth $618,094,000 after buying an additional 3,705,199 shares during the last quarter. BlackRock Investment Management LLC boosted its stake in shares of Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock worth $217,580,000 after buying an additional 3,046,268 shares during the last quarter. Primecap Management Co. CA boosted its stake in shares of Astrazeneca PLC by 17.4% in the second quarter. Primecap Management Co. CA now owns 15,365,950 shares of the company’s stock worth $463,898,000 after buying an additional 2,281,675 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of Astrazeneca PLC by 483.4% in the third quarter. Fisher Asset Management LLC now owns 1,977,585 shares of the company’s stock worth $64,983,000 after buying an additional 1,638,606 shares during the last quarter. 13.05% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE:AZN) traded down 1.408% during mid-day trading on Wednesday, hitting $26.334. 5,559,333 shares of the stock were exchanged. Astrazeneca PLC has a one year low of $25.88 and a one year high of $35.04. The company has a 50-day moving average price of $28.80 and a 200-day moving average price of $30.76. The company has a market cap of $66.63 billion, a P/E ratio of 27.023 and a beta of 0.83.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The company had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter in the previous year, the business posted $1.03 EPS. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, analysts predict that Astrazeneca PLC will post $3.02 earnings per share for the current fiscal year.
A number of brokerages recently commented on AZN. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a research note on Monday, August 8th. Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, October 10th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, November 7th. Bank of America Corp. set a $41.00 price target on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research note on Tuesday, October 4th. Finally, Beaufort Securities reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $37.61.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.